Sanofi (SNY), Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of immune thrombocytopenia in adults.
The recommendation is based on the pivotal LUNA 3 phase 3 study, where Wayrilz met both the primary and secondary endpoints, making LUNA 3 the first phase 3 study to show a positive impact on sustained platelet counts, bleeding, and other ITP symptoms.
The company expects a final decision from the agency in the coming months.
In the pre-market hours, SNY is trading at $50.07, up 0.10 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.